|
| Studies and published years [No] | Diseases |
Cases (T/C) | Intervention regimens |
Time (wk) | Outcomes assessment |
| Treatment group | Control group |
|
|
Liu et al. 2005 [11] | Hepatitis B-caused fibrosis | 110/106 | 0.93 g per FZHY capsule, five capsules orally, tid | 0.93 g per Huoluo Shugan capsule, five capsules orally, tid | 24 | Histologic examination, liver function, liver fibrosis, B ultrasound examination, safety assessment parameter |
|
| Zhao et al. 2006 [26] | Hepatitis B-caused fibrosis | 30/30 | FZHY recipe orally, twice | Conventional protection liver therapeutics | 12 | Clinical syndrome, liver fibrosis |
|
| Hu 2007 [27] | Cirrhosis | 32/30 | 5 FZHY capsules orally, tid | Conventional protection liver therapeutics | 12 | Liver function, liver fibrosis |
|
| Qiu 2010 [28] | Hepatitis B-caused fibrosis | 60/50 | 0.3 g per tablet in FZHY, 1.5 g tid orally | Conventional protection liver therapeutics | 24 | Liver fibrosis |
|
| Wang 2011 [29] | Hepatitis B-caused fibrosis | 60/55 | 0.3 g per tablet in FZHY, 1.5 g tid orally | Conventional protection liver therapeutics | 12 | Liver fibrosis |
|
| Liang et al. 2011 [30] | Posthepatitic cirrhosis | 90/90 | 4 FZHY tablets orally, tid | Conventional protection liver therapeutics, placebo | 24 | Social ability score, liver function, liver fibrosis, coagulation, B ultrasound examination, safety assessment |
|
| Fan and Wu 2012 [31] | Hepatitis B-caused fibrosis | 60/60 | 0.3 g per tablet in FZHY, 1.5 g orally, tid | Conventional protection liver therapeutics | 24 | Liver function, liver fibrosis, B ultrasound examination |
|
| Zhu 2012 [32] | Posthepatitic fibrosis | 28/28 | 0.3 g per tablet in FZHY, 1.5 g orally, tid | 10 g silymarin orally, tid | 24 | Clinical syndrome, liver fibrosis |
|
| Wu and He 2013 [33] | Schistosomiasis hepatic fibrosis | 33/31 | 3 FZHY capsules orally, tid | Conventional protection liver therapeutics | 24 | Clinical syndrome, liver function, liver fibrosis |
|
| Deng et al. 2013 [34] | Posthepatitic cirrhosis | 90/90 | 4 FZHY tablets orally, tid | Four placebo tablets orally, tid | 24 | Liver function, liver fibrosis, coagulation, hemodynamics, degree of esophagogastric varices, score of symptoms and life quality, adverse events, two-year survival |
|
| Song et al. 2013 [14] | Hepatitis B-caused cirrhosis | 110/106 | 0.4 g per tablet in FZHY, 1.6 g orally, tid | 0.4 g per tablet in placebo, 1.6 g orally, tid | 12 | ALT, AST, HA, TCM syndrome score, Child-Pugh |
|
| Wang et al. 2014 [35] | Fibrosis | 30/30 | 3 FZHY tablets orally, tid | 6 g Anluo Huaxian pill orally, twice | 48 | Histologic examination, FibroScan, liver fibrosis, B ultrasound examination |
|
